1. In-Stent CTO Percutaneous Coronary Intervention
- Author
-
Lucio Padilla, Alessio La Manna, Bavana V. Rangan, Dmitrii Khelimskii, Farouc A. Jaffer, Stéphane Rinfret, Pedro Piccaro de Oliveira, Ilias Nikolakopoulos, Ahmed ElGuindy, Karlyse Claudino Belli, Joseph Dens, Lorenzo Azzalini, Pablo Lamelas, Soledad Ojeda, James W. Choi, Simon J Walsh, Alexandre Schaan de Quadros, James C. Spratt, Khaldoon Alaswad, Dimitri Karmpaliotis, Emmanouil S. Brilakis, Mauro Carlino, Evangelia Vemmou, Oleg Krestyaninov, Judit Karacsonyi, Alexandre Avran, Nidal Abi Rafeh, Jaikirshan Khatri, Paul Knaapen, Masaki Tanabe, Pierfrancesco Agostoni, and Manuel Pan
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Stent ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Restenosis ,Internal medicine ,Conventional PCI ,medicine ,Cardiology ,cardiovascular diseases ,030212 general & internal medicine ,Tamponade ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Stroke ,Mace - Abstract
Objectives The authors sought to examine the outcomes of percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) chronic total occlusions (CTOs). Background The outcomes of PCI for ISR CTOs have received limited study. Methods The authors examined the clinical and angiographic characteristics and procedural outcomes of 11,961 CTO PCIs performed in 11,728 patients at 107 centers in Europe, North America, Latin America, and Asia between 2012 and 2020, pooling patient-level data from 4 multicenter registries. In-hospital major adverse cardiovascular events (MACE) included death, myocardial infarction, stroke, and tamponade. Long-term MACE were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization. Results ISR represented 15% of the CTOs (n = 1,755). Patients with ISR CTOs had higher prevalence of diabetes (44% vs. 38%; p Conclusions ISR CTOs represent 15% of all CTO PCIs and can be recanalized with similar success and in-hospital MACE as de novo CTOs.
- Published
- 2021
- Full Text
- View/download PDF